During the 2024 European Society Of Breast Imaging Annual Scientific Meeting, CMR Molecular Imaging invites you to visit its exhibit at Booth #R11.
MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice. Dibble et al. AJR 2020; 215:277–284
RELATED POSTERS AT EUSOBI
A-405
Comparative Performance of Molecular Breast Imaging (MBI) and Magnetic Resonance Imaging (MRI) for Annual Surveillance of Women at High Risk for Breast Cancer.
T. Moseley, et al, MD Anderson Cancer Center, Houston, TX<e/m>
A-154
The Role of PET Mammography as a Problem-Solving Modality for the Diagnosis of the Different Breast Lesions
R. Kamal, et al,, Baheya Foundation Hospital, Cairo, Egypt
LumaGEM®
Ultra low dose imaging O’Connor EUSOBI poster 2019
250% ICDR Rhodes et al. AJR 2015
2x estimated net deaths averted Brown and Covington Radiology: Imaging Cancer 2019